awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q37718444-53160C8D-8E1D-465E-8697-818E287F0AEC
Q37718444-53160C8D-8E1D-465E-8697-818E287F0AEC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37718444-53160C8D-8E1D-465E-8697-818E287F0AEC
Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.
P2860
Q37718444-53160C8D-8E1D-465E-8697-818E287F0AEC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37718444-53160C8D-8E1D-465E-8697-818E287F0AEC
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
c758480b122ee4f27548cf400c3d4878671485bb
P2860
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer